Innate Pharma Reports FY 2025 Results and FDA Clearance for Phase 3 Lacutamab Trial

Innate Pharma SA has released its consolidated financial results for the fiscal year ending December 31, 2025, alongside a strategic business update. A key highlight of the report is the successful clearance from the US Food and Drug Administration (FDA) regarding the design of the TELLOMAK-3 study. This regulatory milestone paves the way for the company to initiate a confirmatory Phase 3 trial for its lead immunotherapy candidate, lacutamab. The transition to late-stage clinical testing represents a significant step forward in the company's oncology pipeline development. Investors are closely monitoring these clinical advancements as they underscore the potential for future commercialization. Despite the focus on clinical progress, the company remains committed to maintaining a solid financial foundation to support its ongoing research initiatives.